Himuka AM Pharma Corp.

Establishment Date February 2017
Business Developing drug seeds with a strong focus on derivatives of a bioactive peptide adrenomedullin (AM) which was discovered at University of Miyazaki (formerly Miyazaki Medical College)
CEO Hiroshi Shinjo
URL http://www.himuka-am.com/

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.

同意するAgree